CSI Market
Sign In | Register

Neos Therapeutics Inc (NEOS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access NEOS Annual Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Neos Therapeutics Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2020)
9 Months 		(Jun 30 2020) (Mar 31 2020) (Dec 31 2019) (Sep 30 2019)
Operating Activities
Income-18.37
Depreciation & amortization1.44
Amortization of Other Assets1.79
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories2.57
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.32
Share-based Compensation2.25
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Amortization Of Intangible Assets Excluding Patents-
Fair Value Adjustment Of Earnout Liabilities And Warrant Liabilities0.32
Amortization Of Patents-
Interest Accrued On Debt-
Noncash Portion Of Gains Losses On Extinguishment Of Debt-
Income taxes-0.10
Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments0.00
Increase (Decrease) in Accounts Receivable6.18
Increase (Decrease) in Accounts Payable1.90
Increase (Decrease) in Accrued Liabilities-8.95
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Deferred Charges0.00
Other Working Capital1.54
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities1.47
Discontinued operations0.00
Net Cash flow from Operating Activities-7.64
Investing Activities
Capital Expenditures-0.28
Sale of Capital Items0.00
Proceeds from Sale of Available-for-sale Securities, Debt11.09
Payments to Acquire Available-for-sale Securities, Debt-2.99
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities7.82
Financing Activities
Short-term debt Net7.32
Other borrowing transactions-0.15
Long-term debt - borrowings3.58
Long-term debt - repayments-7.85
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-7.17
Proceeds From Stock Options And Warrants Exercised-
Sale Of Stock Consideration Received On Transaction0.00
Payment Of Payroll Taxes Withheld For Releases Of Restricted Stock Units-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-4.26
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-7.92
Total Cash Flow-4.09
4 historic quarters locked

Sign in to unlock the full Neos Therapeutics Inc cash flow history.

Sign In Create Free Account

About NEOS Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.